HCA
IMNM icon

Harbor Capital Advisors’s Immunome IMNM Stock Holding History

Harbor Capital Advisors’s Portfolio IMNM Stock Details IMNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-19,855
Closed -$426K – 1357
2025
Q4 		$426K Buy
+19,855
New +$348K 0.03% 531

Other funds holding IMNM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return

Harbor Capital Advisors's IMNM Position: Q1 2026 in Review

Harbor Capital Advisors sold out of Immunome (IMNM) in Q1 2026, closing a stake of 19,855 shares — an estimated $426K sold.

Harbor Capital Advisors first reported a position in IMNM in Q4 2025 and held it in 1 quarter. The position peaked at $426K in Q4 2025. 200 funds tracked by Wall St. Rank hold IMNM as of Q1 2026.

  • Harbor Capital Advisors reported no remaining Immunome position as of Q1 2026 after selling out during the quarter.
  • Harbor Capital Advisors sold 19,855 Immunome shares in Q1 2026, an estimated $426K.
  • Harbor Capital Advisors first reported a position in Immunome in Q4 2025 and held it in 1 quarter.
  • Harbor Capital Advisors's Immunome position peaked at $426K in Q4 2025.
  • 200 funds tracked by Wall St. Rank held Immunome as of Q1 2026.

Based on Harbor Capital Advisors's 13F filing for Q1 2026, filed 28 Apr 2026.